Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 8068

Next Previous
Drug Profile

SHR 8068

Alternative Names: SHR-8068

Latest Information Update: 25 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Biliary cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase I/II Urogenital cancer

Most Recent Events

  • 19 Jun 2025 Suzhou Suncadia Biopharmaceuticals plans a phase II trial for Solid tumours (Combination therapy) in June 2025 (Unspecified) (NCT07028281)
  • 25 Mar 2025 Suzhou Suncadia Biopharmaceuticals plans a phase Ib/II trial for Cervical cancer (Recurrent, Metastatic disease, Combination therapy) in China (Parenteral), in March 2025 (NCT06859775)
  • 07 Mar 2025 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease) in China (IV) (NCT06844474)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top